Viral infections:
Indications for: RAPIVAB
Treatment of acute uncomplicated influenza in patients who have been symptomatic for ≤2 days.
Limitations of Use:
Efficacy based on predominantly influenza A virus infections; limited number of influenza B virus subjects were enrolled. Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. Efficacy not established in patients with serious influenza requiring hospitalization.
Adult Dosage:
Start within 2 days of symptom onset. Give as IV infusion over 15–30mins. ≥13yrs: 600mg as a single dose. Renal impairment (CrCl 30–49mL/min): 200mg; (CrCl 10–29mL/min): 100mg; (on hemodialysis): give after dialysis.
Children Dosage:
<6months: not established. Start within 2 days of symptom onset. Give as IV infusion over 15–30mins. 6months–12yrs: 12mg/kg as a single dose (max 600mg). Renal impairment: 6months–<2yrs (CrCl <50mL/min): no data; 2–12yrs (CrCl 30–49mL/min): 4mg/kg; (CrCl 10–29mL/min): 2mg/kg; (on hemodialysis): give after dialysis.
RAPIVAB Warnings/Precautions:
Discontinue if anaphylaxis or serious skin reaction (eg, erythema multiforme, Stevens-Johnson syndrome) occurs or is suspected. Monitor closely for signs of abnormal behavior. Risk of secondary bacterial infections; treat as appropriate. Pregnancy. Nursing mothers.
RAPIVAB Classification:
Neuraminidase inhibitor.
RAPIVAB Interactions:
Avoid live attenuated influenza vaccine within 2wks prior or 48hrs after treatment.
Adverse Reactions:
Diarrhea; neuropsychiatric events (eg, hallucinations, delirium, abnormal behavior); rare: serious skin reactions, anaphylaxis.
Generic Drug Availability:
NO
How Supplied:
Single-use vials (20mL)—3
